商品编号


F6171



品牌


UBPBio



公司


Ubiquitin-Proteasome Biotechnologies, LLC



公司分类


Inhibitors



Size

25 mg

商品信息

GDC-0068 (RG7440 or Ipatasertib) is a novel, ATP-competitive Akt1/2/3 inhibitor with IC50 values of 5 nM, 18 nM and 8 nM, respectively. GDC-0068 selectively inhibits cell cycle progression and vi
ABI
lity of cancer cell lines driven by PI3K/Akt signaling pathway, including those with defects of the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2. GDC-0068 blocks the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.

Additional Information






Product Name:

GDC-0068 (RG7440, Ipatasertib)



Also Known As:

Ipatasertib, (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one



Catalog No.:

F6171



Size:

25 mg



CAS:

1001264-89-6



Formula:

C
24
H
32
ClN
5
O
2



Molecular Weight:

458 Da



Form:

Lyophilized powder



Quality Assurance:

>98% by HPLC and NMR



Source:

Synthetic



Storage:

Elig
IBL
e for room temperature shipping. Store at -80°C upon receiving



PDF Data Sheet:

Download PDF datasheet



Image(s):

N/A



Shipping Method:

Room temperature shipping



References:

Blake JF,
et al
. (2012) J Med Chem. 55(18):8110-27.




Details

GDC-0068 (RG7440 or Ipatasertib) is a novel, ATP-competitive Akt1/2/3 inhibitor with IC50 values of 5 nM, 18 nM and 8 nM, respectively. GDC-0068 selectively inhibits cell cycle progression and vi
ABI
lity of cancer cell lines driven by PI3K/Akt signaling pathway, including those with defects of the tumor suppressor PTEN, oncogenic mutations in PIK3CA, and amplification of HER2. GDC-0068 blocks the phosphorylation of multiple downstream targets of Akt in human cancer cell lines.

Solubility:

> 20 mg/ml in DMSO